Variant of concern

The variant was first identified on November 9 and reported to the World Health Organization (WHO) on November 24. Two days later, the WHO designated the coronavirus variant B.1.1.529 a variant of concern, or VOC, and gave it the name Omicron.

The health organization said Omicron "has a large number of mutations, some of which are concerning." A mutation is a change in the genetic material of a virus. The WHO added that early evidence suggests "an increased risk of reinfection with this variant, as compared to other VOCs."

Scientists still do not know whether the mutated versions could make it more dangerous. But the WHO said, "There is currently no information to suggest that symptoms associated with Omicron are different from those from other variants."

Dr. Angelique Coetzee, a South African doctor who was one of the first to identify Omicron, spoke to Reuters. She said that symptoms of the variant were not severe and could be treated at home.

Vaccines against Omicron

It is also unknown whether currently approved vaccines or treatments will protect against the variant.

Dr. Francis Collins is head of the U.S. National Institutes of Health. He told Fox News Sunday, "We do know that this is a variant that has a lot of mutations – like 50 of them, and more than 30 of those in the spike protein, which is the part of the virus that attaches to your human cells if you get infected."

Collins added, "It does make you worry, therefore, that it's a sufficiently different virus, that it might not respond as well to protection from the vaccines. But we don't know that."

On Friday, American drug-maker Pfizer and its German partner BioNTech said new information would show whether their vaccine will have to be changed. The companies said, if necessary, they expect to be able to ship a new vaccine against Omicron in about 100 days. The Pfizer vaccine uses mRNA technology which uses RNA genetic material to change cells.

Moderna is the maker of the other highly effective mRNA vaccine. It said it is working on a booster designed to protect against several variants. And Johnson & Johnson stated that it was already testing their vaccine against Omicron.

Vaccines, however, are still not widely available in poor and developing countries. In Africa, where Omicron was first reported, only seven percent of the continent's 1.2 billion people have received the shots so far.

Post time: Dec-27-2021